The Biden administration has released the list of the first ten drugs that will be subject to Medicare price negotiations. The Center for Medicare Director Dr. Meena Seshamani tells Yahoo Finance Live that they are looking at "the benefits that a drug brings to populations. Does it address an unmet need? Does it address different populations that have needs?" When it comes to why some drugs were chosen Dr. Seshamani says the organization followed the criteria written in the Inflation Reduction Act, adding that the list will not change.
These are the ten drugs Medicare will be negotiating the prices of:
Eliquis- Bristol-Myers Squibb (BMY), Pfizer (PFE)
Jardiance- Boehringer Ingelheim, Eli Lilly (LLY)
Xarelto- Bayer (BAYRY), Johnson & Johnson (JNJ)
Januvia- Merck (MRK)
Farxiga- AstraZeneca (AZN)
Entresto- Novartis (NVS)
Enbrel- Amgen (AMGN)
Imbruvica- Johnson & Johnson (JNJ), AbbVie (ABBV)
Stelara- Johnson & Johnson (JNJ)
Fiasp, NovoLog- Novo Nordisk (NVO)
